---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-082809"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2025-04-16T23:59:59+00:00"
generated_at: "2026-05-23T13:00:18.853332+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Acadia Pharmaceuticals amends bylaws, tightens stockholder nomination and meeting rules

## Summary
- Quorum threshold changed from majority of outstanding shares to majority of voting power.
- Stockholder nominees limited to number of directors to be elected; substitute nominees prohibited.
- Advance notice window widened: alternative window applies if annual meeting delayed >70 days (was 30).
- Mandatory indemnification and expense advancement for directors/officers expanded to maximum extent allowed.
- Exclusive forum provisions clarified, including U.S. federal district courts for Securities Act claims.

## SEC filing metadata
- accession: 0001193125-25-082809
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2025-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312525082809/0001193125-25-082809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312525082809/d905282d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-082809
- JSON: https://secwatch.observer/filing/0001193125-25-082809.json
- Plain text: https://secwatch.observer/filing/0001193125-25-082809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.